title: Structures and free energy landscapes of the wild-type and A30P mutant-type α-synuclein proteins with dynamics.
abstract: The genetic missense A30P mutation of the wild-type α-synuclein protein results in the replacement of the 30th amino acid residue from alanine (Ala) to proline (Pro) and was initially found in the members of a German family who developed Parkinson's disease. Even though the structures of these proteins have been measured before, detailed understanding about the structures and their relationships with free energy landscapes is lacking, which is of interest to provide insights into the pathogenic mechanism of Parkinson's disease. We report the secondary and tertiary structures and conformational free energy landscapes of the wild-type and A30P mutant-type α-synuclein proteins in an aqueous solution environment via extensive parallel tempering molecular dynamics simulations along with thermodynamic calculations. In addition, we present the residual secondary structure component transition stabilities at the atomic level with dynamics in terms of free energy change calculations using a new strategy that we reported most recently. Our studies yield new interesting results; for instance, we find that the A30P mutation has local as well as long-range effects on the structural properties of the wild-type α-synuclein protein. The helical content at Ala18-Gly31 is less prominent in comparison to the wild-type α-synuclein protein. The β-sheet structure abundance decreases in the N-terminal region upon A30P mutation of the wild-type α-synuclein, whereas the NAC and C-terminal regions possess larger tendencies for β-sheet structure formation. Long-range intramolecular protein interactions are less abundant upon A30P mutation, especially between the NAC and C-terminal regions, which is linked to the less compact and less stable structures of the A30P mutant-type rather than the wild-type α-synuclein protein. Results including the usage of our new strategy for secondary structure transition stabilities show that the A30P mutant-type α-synuclein tendency toward aggregation is higher than the wild-type α-synuclein but we also find that the C-terminal and NAC regions of the A30P mutant-type α-synuclein are reactive toward fibrillzation and aggregation based on atomic level studies with dynamics in an aqueous solution environment. Therefore, we propose that small molecules or drugs blocking the specific residues, which we report herein, located in the NAC- and C-terminal regions of the A30P mutant-type α-synuclein protein might help to reduce the toxicity of the A30P mutant-type α-synuclein protein.
authors: Department of Chemistry, The University of Texas at San Antonio, One UTSA Circle, San Antonio, TX 78249, USA.
authors: Olivia
authors: O
authors: Wise-Scira
authors: Ahmet Kemal
authors: AK
authors: Aloglu
authors: Aquila
authors: A
authors: Dunn
authors: Isin Tuna
authors: IT
authors: Sakallioglu
authors: Orkid
authors: O
authors: Coskuner
mesh_terms: D000409:Alanine / Q000737:chemistry / Q000235:genetics*; D004734:Energy Metabolism / Q000235:genetics; D006801:Humans; D056004:Molecular Dynamics Simulation; D050505:Mutant Proteins / Q000737:chemistry / Q000235:genetics*; D020125:Mutation, Missense / Q000235:genetics*; D011392:Proline / Q000737:chemistry / Q000235:genetics*; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D051844:alpha-Synuclein / Q000737:chemistry / Q000235:genetics*
chemical_list: D050505:Mutant Proteins; D051844:alpha-Synuclein; D011392:Proline; D000409:Alanine
references: Neurotoxicology. 2002 Oct;23(4-5):553-67
references: 12428728
references: Biochemistry. 2004 May 11;43(18):5539-50
references: 15122920
references: J Biol Chem. 2001 Dec 7;276(49):45996-6003
references: 11590151
references: J Neural Transm (Vienna). 2000;107(1):31-40
references: 10809401
references: Nature. 1997 Aug 28;388(6645):839-40
references: 9278044
references: Chembiochem. 2009 Jan 5;10(1):176-83
references: 19067456
references: J Biol Chem. 2009 Mar 13;284(11):7177-89
references: 19126542
references: FEBS Lett. 1998 Nov 27;440(1-2):67-70
references: 9862427
references: Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):571-6
references: 10639120
references: Biochemistry. 2001 Sep 25;40(38):11604-13
references: 11560511
references: Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4897-902
references: 10781096
references: Science. 1997 Jun 27;276(5321):2045-7
references: 9197268
references: Proteins. 2004 May 1;55(2):383-94
references: 15048829
references: Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4194-9
references: 21325059
references: Phys Chem Chem Phys. 2008 Apr 21;10(15):2073-7
references: 18688361
references: ACS Chem Neurosci. 2013 Mar 20;4(3):498-508
references: 23374074
references: Eur Biophys J. 2012 May;41(5):483-9
references: 22446722
references: Science. 2003 Oct 31;302(5646):841
references: 14593171
references: Proteins. 2000 Jun 1;39(4):309-16
references: 10813813
references: J Chem Phys. 2011 Nov 28;135(20):205101
references: 22128957
references: Biochem Biophys Res Commun. 2009 Sep 18;387(2):305-9
references: 19580781
references: Biochem Biophys Res Commun. 2007 Apr 6;355(2):398-403
references: 17300751
references: Nat Genet. 1998 Feb;18(2):106-8
references: 9462735
references: J Biol Chem. 1999 Mar 19;274(12):7619-22
references: 10075647
references: Science. 1996 Nov 15;274(5290):1197-9
references: 8895469
references: Biochem Biophys Res Commun. 2009 Oct 2;387(4):682-7
references: 19622344
references: J Mol Biol. 2002 Jan 25;315(4):799-807
references: 11812148
references: J Chem Phys. 2005 Oct 15;123(15):154105
references: 16252940
references: Neurosci Lett. 2003 May 15;342(1-2):124-8
references: 12727333
references: Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16466-71
references: 15536128
references: Ann Neurol. 2004 Feb;55(2):164-73
references: 14755719
references: ACS Chem Neurosci. 2013 Feb 20;4(2):310-20
references: 23421682
references: Neurobiol Dis. 2011 Sep;43(3):715-24
references: 21684335
references: J Biol Chem. 1999 Apr 2;274(14):9843-6
references: 10092675
references: Biopolymers. 1983 Dec;22(12):2577-637
references: 6667333
references: Clin Chem Lab Med. 2001 Apr;39(4):308-12
references: 11388653
references: Proteins. 2006 Nov 15;65(3):712-25
references: 16981200
references: Neurotoxicology. 2011 Dec;32(6):857-63
references: 21658409
references: Nat Med. 1998 Nov;4(11):1318-20
references: 9809558
references: J Neurosci. 1988 Aug;8(8):2804-15
references: 3411354
references: Angew Chem Int Ed Engl. 2010 May 3;49(20):3469-72
references: 20544898
references: J Biol Chem. 2005 Sep 2;280(35):30649-52
references: 16020550
references: Trends Neurosci. 1998 Jun;21(6):249-54
references: 9641537
references: Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1430-5
references: 15671169
references: Biochemistry. 2001 Jul 3;40(26):7812-9
references: 11425308
references: Acc Chem Res. 2000 Dec;33(12):889-97
references: 11123888
references: Biochemistry. 2003 Jan 28;42(3):672-8
references: 12534279
references: J Mol Biol. 2002 Oct 4;322(5):1089-102
references: 12367530
references: J Biol Chem. 2001 Jan 26;276(4):2380-6
references: 11060312
references: Science. 1991 Jul 12;253(5016):179-82
references: 1853202
references: J Biol Inorg Chem. 2012 Aug;17(6):927-38
references: 22674434
references: Biochemistry. 2011 Aug 16;50(32):6994-7001
references: 21736378
references: Protein Sci. 2011 Feb;20(2):387-95
references: 21280130